GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Total Current Liabilities

Roquefort Therapeutics (LSE:ROQ) Total Current Liabilities : £0.31 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Roquefort Therapeutics's total current liabilities for the quarter that ended in Dec. 2023 was £0.31

Roquefort Therapeutics Total Current Liabilities Historical Data

The historical data trend for Roquefort Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Total Current Liabilities Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Current Liabilities
0.20 0.28 0.31

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23
Total Current Liabilities 0.01 1.09 0.28 0.37 0.31

Roquefort Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Roquefort Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.145+0
+Other Current Liabilities+Current Deferred Liabilities
=0.162+0
=0.31

Roquefort Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.145+0
+Other Current Liabilities+Current Deferred Liabilities
=0.162+0
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Roquefort Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Total Current Liabilities
Comparable Companies
AQSE:PBX LSE:BSFA LSE:BVX LSE:IMM LSE:OCTP LSE:CIZ LSE:IXI LSE:APTA LSE:ONC LSE:VAL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ROQAF:USA
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Website
https://www.roquefortplc.com
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines